Pharmacokinetic parameters of sulfated tibolone metabolites in postmenopausal women after single and multiple doses of tibolone

Clinical Pharmacology and Therapeutics

Volumn 81, Issue 4, 2007, Pages 573-579

  Verheul, H A M ^a   Timmer, C J ^b   Kloosterboer, H J ^a  

^a NV ORGANON   (Netherlands)

^b NV Organon ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3ALPHA HYDROXYTIBOLONE; 3ALPHA,17BETA DISULFATE TIBOLONE; DELTA 4 TIBOLONE; DRUG METABOLITE; PLACEBO; TIBOLONE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG METABOLISM; DRUG SULFATION; GAS CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLIC PARAMETERS; MULTIPLE CYCLE TREATMENT; MULTIPLE DRUG DOSE; OPEN STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VALIDATION STUDY;

BIOTRANSFORMATION; DOUBLE-BLIND METHOD; EDETIC ACID; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; HYDROXYLATION; MIDDLE AGED; NORPREGNENES; POSTMENOPAUSE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SULFATES;

EID: 33947417775     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100094     Document Type: Article

References (17)

1. Kloosterboer, H.J. Tissue-selectivity: the mechanism of action of tibolone. Maturitas 49(Suppl1), S30-S40 (2004).
2. Rymer, J., Robinson, J. & Fogelman, I. Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women. Climacteric 5, 390-398 (2005).
3. Landgren, M.B., Helmond, F.A. & Engelen, S. Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot flashes and sweats per day. Maturitas 50, 222-230 (2005).
4. Vos, R.M.E., Krebbers, S.F.M., Verhoeven, C.H.J. & Delbressine, L.P.C. The in vivo human metabolism of tibolone. Drug Metab. Dispos. 30, 106-112 (2002).
5. Timmer, C.J. & Huisman, J.A.M. Effect of a standardized meal on the bioavailability of a single oral dose of tibolone 2.5 mg in healthy postmenopausal women. Pharmacotherapy 22, 310-315 (2002).
6. Timmer, C.J., Verheul, H.A.M. & Doorstam, D.P. Pharmacokinetics of tibolone in early and late postmenopausal women. Br. J. Clin. Pharmacol. 54, 101-106 (2002).
7. Timmer, C.J. & Houwing, N.S. Dose proportionality of three different doses of tibolone. Pharmacotherapy 22, 6-13 (2002).
8. Timmer, C.J. & Doorstam, D.P. Effect of renal impairment on the pharmacokinetics of a single oral dose of tibolone 2.5 mg in early postmenopausal women. Pharmacotherapy 22, 148-153 (2002).
9. Gooyer, M.E., de Deckers, G.H., Schoonen, W.G.E.J., Verheul, H.A.M. & Kloosterboer, H.J. Receptor profiling and endocrine interactions of tibolone. Steroids 68, 21-30 (2003).
10. Steckelbroeck, S., Jin, Y., Oyesanmi, B., Kloosterboer, H.J. & Penning, T.M. Tibolone is metabolized by the 3alpha/3beta-hydroxysteroid dehydrogenase activities of the four human isozymes of the aldo-keto reductase 1C subfamily: Inversion of stereospecificity with a delta5(10)-3- ketosteroid. Mol. Pharmacol. 66, 1702-1711 (2004).
11. Falany, J.L., Macrina, N. & Falany, C.N. Sulfation of tibolone and tibolone metabolites by expressed human cytosolic sulfotransferases. J. Steroid Biochem. Mol. Biol. 88, 383-391 (2004).
12. Wang, M., Ebmeier, C.C., Olin, J.R. & Anderson, R.J. Sulfation of tibolone metabolites by human postmenopausal liver and small intestinal sulfotransferases. Steroids 71, 343-351 (2005).
13. Gallagher, J.C., Baylink, D.J., Freeman, R. & McClung, M. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose finding studies. J. Clin. Endocrinol. Metab. 86, 4717-4726 (2001).
14. Stecklebroeck, S., Oyesanmi, B., Jin, Y., Lee, S.-H., Kloosterboer, H.J. & Penning, T.M. Tibolone metabolism in human liver is catalyzed by 3α/3β-hydroxysteroid dehydrogenase activities of the four isoforms of the aldo-keto reductase (AKR)1C subfamily. J. Pharmacol. Exp. Ther. 316, 1300-1309 (2006).
15. Gooyer, M.E., de Overklift Vaupel Kleyn, G.T., Smits, K.C., Ederveen, A.G.H., Verheul, H.A.M. & Kloosterboer, H.J. Tibolone: a compound with tissue specific inhibitory effects on sulfatase. Mol. Cell Endocrinol. 183, 55-62 (2001).
16. Shah, V.P., et al. Workshop/Conference report; Bioanalytical Method Validation. A revisit with a decade of progress. Pharmaceut. Res. 17, 1551-1557 (2000).
17. Biopharmaceutics Coordinating Committee. Guidance for Industry, Bioanalytical Methods Validation, US Department of Health and Human Services, Food and Drug Administration, Center for Drug evaluation and Research (CDER), Center for Veterinary Medicine (CVM): Rockville, USA (2001).